Case Study

Exceeding Expectations: TFS Accelerates Patient Recruitment for a Global Phase III Prurigo Nodularis Study

February 2, 2021February 28th, 2025

Exceeding Expectations: TFS Accelerates Patient Recruitment for a Global Phase III Prurigo Nodularis Study

Discover how TFS accelerated patient recruitment for a global Phase III prurigo nodularis study, exceeding enrollment expectations despite unique challenges. This case study explores TFS’s strategic approach and effective solutions that drove remarkable success.

What You’ll Learn:

  • How TFS overcame recruitment challenges for a rare disease in an aging patient population
  • Key strategies for proactive enrollment management and patient-centric solutions
  • The impact of strategic site selection and effective project management on study timelines

Download the complete case study to explore the innovative strategies and expert insights that led to this outstanding achievement.

Learn more about our related services and resources:

TFS Dermatology

Connect with Us

Contact us today to discover how TFS can be your strategic CRO partner in clinical development.

Let's Talk

Learn More About Our Dermatology Expertise

Managing Placebo Risk in Dermatology TrialsWebinars

Managing Placebo Risk in Dermatology Trials

Gain practical strategies for managing placebo risk and ensuring credible, compliant dermatology trial results.
Global support for sponsors running psoriasis clinical trials
Top 5 Challenges in Psoriasis Clinical Trials (and How to Overcome Them)Article

Top 5 Challenges in Psoriasis Clinical Trials (and How to Overcome Them)

Psoriasis clinical trials face predictable hurdles, from patient recruitment shortfalls to regulatory complexity. This blog explores the five most common challenges and practical strategies sponsors can use to overcome them.
atopic dermatitis trial design
Emerging Therapies for Atopic DermatitisWhite paper

Emerging Therapies for Atopic Dermatitis

Learn more about next-generation clinical research in atopic dermatitis with insights into new therapeutic targets, disease endotyping, and smarter trial design.